DINA BEDWANI: Open Payments
NPI 1184008641 · THOUSAND OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,506 in 44 payments from 13 companies in 2025. Trend: 2023 $981 · 2024 $1,075 · 2025 $1,506
Food & beverage: $1,506
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 6 | $482 |
| Amgen Inc. | 10 | $318 |
| Novartis Pharmaceuticals Corporation | 8 | $169 |
| Alnylam Pharmaceuticals Inc. | 2 | $131 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $97 |
| PFIZER INC. | 4 | $87 |
| AstraZeneca Pharmaceuticals LP | 3 | $57 |
| BridgeBio Pharma, Inc. | 1 | $38 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Merck Sharp & Dohme LLC | 1 | $32 |
Products named: REPATHA, FARAPULSE, LEQVIO, AMVUTTRA, WATCHMAN Access System, EMBLEM MRI S-ICD, Kerendia, VYNDAQEL.
Industry payments across CA — which companies pay providers there.
